The Beauty Health pany(SKIN) GlobeNewswire·2025-03-12 20:05Core Insights - The Beauty Health Company reported fourth quarter net sales of 334.3 million, down 16.0% year-over-year [10][3][4] - The company achieved an adjusted EBITDA of 3.4 million in Q4 2023, driven by increased consumable sales and reduced operating expenses [2][10] - Gross margin improved to 62.7% in Q4 2024 from 47.2% in Q4 2023, attributed to lower inventory-related charges and a favorable shift towards consumable sales [10][3] Financial Performance - For Q4 2024, delivery systems net sales were 44.6 million in Q4 2023, while consumables net sales increased to 52.2 million [3][11] - The full year gross profit was 155.1 million in 2023, with an adjusted gross margin of 62.0% compared to 62.8% in the previous year [10][3] - The net loss for 2024 was (100.1) million in 2023, reflecting reduced costs associated with the Syndeo Program [10][3] Operational Metrics - The company placed 1,087 delivery systems in Q4 2024, down from 1,551 in Q4 2023, and a total of 4,907 systems for the year, compared to 8,287 in 2023 [10][3] - The active install base grew to 34,735 units by the end of 2024, up from 31,446 units in 2023, contributing to the increase in consumable sales [4][3] - The company plans to transition its China market from a direct sales model to a distributor model in 2025 [4] Guidance and Future Outlook - For Q1 2025, the company expects net sales between 66 million, with an adjusted EBITDA loss projected between (4) million [8] - Full year 2025 guidance anticipates net sales of 300 million and adjusted EBITDA of 25 million, reflecting ongoing challenges in delivery systems sales [8][9] - The company aims to deepen partnerships and accelerate science-backed innovations in 2025 despite macroeconomic uncertainties [2]